Payment overview · 2025
General Payments
$69.92
4 reported records · 4 companies
Healthcare provider profile · identity verified
Sara L Johnston, MD
Allopathic & Osteopathic Physicians|Family Medicine · SALINA, KS · NPI 1740245638
Verified facts
What the public records show
CMS Open Payments records show Sara L Johnston, MD received $69.92 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.38 | 29.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.91 | 28.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.47 | 22.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.16 | 20.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $69.92 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 114 |
| Lisinopril | Lisinopril | 415 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 73 |
| Omeprazole | Omeprazole | 295 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 42 |
| Losartan Potassium | Losartan Potassium | 178 | 49 |
| Atenolol | Atenolol | 170 | 34 |
| Sertraline Hcl | Sertraline Hcl | 158 | 27 |
| Simvastatin | Simvastatin | 150 | 32 |
| Gabapentin | Gabapentin | 149 | 34 |
| Spironolactone | Spironolactone | 147 | 23 |
| Furosemide | Furosemide | 138 | 31 |
| Eliquis | Apixaban | 122 | 17 |
| Potassium Chloride | Potassium Chloride | 121 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 28 |
| Metformin Hcl | Metformin Hcl | 118 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 25 |
| Warfarin Sodium | Warfarin Sodium | 108 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 27 |
| Tramadol Hcl | Tramadol Hcl | 105 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 25 |
| Celecoxib | Celecoxib | 87 | 18 |
| Ozempic | Semaglutide | 81 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 14 |
| Farxiga | Dapagliflozin Propanediol | 74 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 73 | 16 |
| Mirtazapine | Mirtazapine | 73 | 13 |
| Buspirone Hcl | Buspirone Hcl | 71 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 12 |
| Estradiol | Estradiol | 64 | 21 |
| Donepezil Hcl | Donepezil Hcl | 62 | suppressed |
| Pregabalin | Pregabalin | 62 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Ezetimibe | Ezetimibe | 59 | 12 |
| Montelukast Sodium | Montelukast Sodium | 59 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 13 |
| Meloxicam | Meloxicam | 56 | 17 |
| Azithromycin | Azithromycin | 55 | 43 |
| Alprazolam | Alprazolam | 53 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 13 |
| Clonazepam | Clonazepam | 52 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Amoxicillin | Amoxicillin | 50 | 32 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 12 |
| Prednisone | Prednisone | 48 | 28 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 13 |
| Famotidine | Famotidine | 41 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Torsemide | Torsemide | 41 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | 12 |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 13 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 13 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Modafinil | Modafinil | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Allopurinol | Allopurinol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Fluconazole | Fluconazole | 21 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | 12 |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $69.92 · 4 records | PFIZER INC. | ABRYSVO, BEXSERO, LEQVIO, Ozempic, PEDIARIX, PENMENVY, PREVNAR 20, Rybelsus | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error